The bowel refers to the lowermost portion of the gastrointestinal (GI) tract. Structural or biochemical abnormalities associated with the bowel can give rise to a variety of disorders, with common examples including ulcerative colitis and Crohn’s disease, collectively termed inflammatory bowel disease. In the case of ulcerative colitis, there is chronic inflammation of the colon and rectum. Meanwhile in Crohn’s disease, though inflammation may occur anywhere along the gut, it most frequently manifests in the ileum.
Featured Learning Zones
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Inflammatory Bowel Disease
Treatment options for inflammatory bowel disease (IBD) are evolving as knowledge of the condition is increasing. In the future, physicians may be able to offer therapy tailored to individual patients. This Learning Zone describes the background behind such advances.
Recurrent or persistent abdominal pain, diarrhoea, fatigue and loss of appetite are some of the symptoms most frequently reported by patients with bowel disorders. Treatment of bowel disorders can prove challenging; however alleviation of symptoms may be achieved through dietary alterations or pharmacological interventions.
To find out more about the diagnosis and treatment of some of the most common bowel disorders, visit our dedicated “Anti-integrins in IBD” and “Inflammatory bowel disease assessment tools” Learning Zones, with a disease overview available in our Inflammatory Bowel Disease Knowledge Centre.
Related news and insights
AbbVie announced that Rinvoq (upadacitinib 45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints in the Phase III induction study, U-ACCOMPLISH in adults with moderate to severe ulcerative colitis.
AbbVie announced positive results from two Phase III induction studies, ADVANCE and MOTIVATE, showing both doses of Skyrizi (risankizumab) (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscopic response at week 12 in adult patients with moderate to severe Crohn's disease.
The guideline has been condensed into two papers,[...] the second describing current therapeutic management [treatment of active disease and maintenance of medically induced remission].
The goal of this consensus initiated by the European Crohn’s and Colitis Organisation [ECCO] and European Society of Colo-Proctology [ESCP] was to establish European consensus guidelines for the surgical treatment of Crohn’s disease [CD].